Enbrel Patent Protection
0 patents · Amgen Inc., Pfizer Inc.
Biosimilar Pathway
Enbrel (etanercept) is a biologic, not a small-molecule drug. Biologics are not listed in the FDA Orange Book and do not face conventional “generic” competition. Instead, follow-on competitors called biosimilars can be approved through the FDA’s BPCIA pathway, typically after the reference product’s 12-year exclusivity period and the resolution of any patent litigation.
For the current biosimilar approvals and exclusivity status of Enbrel, see the authoritative FDA Purple Book listing for etanercept.
Related Drug Patent Expirations
2 patents · earliest expires 2027 · Bristol-Myers Squibb Company
3 patents · earliest expires 2027 · Pfizer Inc.
22 patents · earliest expires 2028 · Pfizer Inc.
7 patents · earliest expires 2026 · Astellas Pharma Inc.
0 patents · Genentech Inc.
9 patents · earliest expires 2033 · Gilead Sciences Inc.
For Enbrel, the underlying data on this page comes from the FDA Orange Book and USPTO patent records. The breakdown above is the federal record; the paragraphs below add the per-entity context that makes the headline numbers usable for a real decision rather than just a data lookup.
Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for Enbrel is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.